Fundraising FoxDecade
4 known investors
Find your way into Decade
Sign up to see every warm intro you have to Decade
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Decade team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Decade develops targeted cancer therapies using AI and high-throughput data analysis to match treatments to individual patients' tumor molecular profiles.
Also known as Decade
Investors · 4
How we know: Tau Ventures's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
Company profile
researched Sep 2026Decade is a biotechnology company focused on oncology drug development. It applies artificial intelligence, high-throughput data generation and analysis, and cancer biology research to design targeted therapies aimed at the distinct molecular signatures found in individual patients' tumors.
▸Full profile — technology
Technology
The company's approach combines AI methods with high-throughput data and cancer biology expertise to identify and develop therapies directed at tumor-specific molecular features.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 8
primary sources listed
- Decadedecade.bio · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Decade do?
- Decade develops targeted cancer therapies matched to the molecular signature of an individual patient's tumor.
- Who are Decade's investors?
- Decade's investors include 500 Global, Tau Ventures, Benchmark, Greenoaks.